The future of real world evidenceIncreasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role Share XThe future of real world evidencehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/
FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention useBayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA Share XFDA approves Bayer/Janssen’s Xarelto in new blood clot prevention usehttps://pharmaphorum.com/news/fda-approves-bayer-janssens-xarelto-in-new-blood-clot-prevention-use/
Keytruda wins another first with approval based on biomarkersFor the first time, FDA approves drug on the basis of biomarkers, rather than location. Share XKeytruda wins another first with approval based on biomarkershttps://pharmaphorum.com/news/merck-cancer-biomarkers-keytruda/